Signos: AI-Powered CGM for Weight Management and Metabolic Health

The connection between blood sugar and body weight has been studied for decades. Now AI is using real-time glucose data to guide when, what, and how much you eat.

Weight management has historically operated on a simple input-output model: calories in versus calories out. But a growing body of metabolic research has revealed that the story is far more nuanced. Two people can eat identical meals and experience dramatically different glucose responses, insulin surges, and downstream fat storage signals. The variability is driven by genetics, gut microbiome composition, sleep quality, stress hormones, and the metabolic efficiency of the individual’s cells. A calorie is not simply a calorie when the hormonal response it triggers varies by a factor of two or three between individuals.

Signos is a CGM-as-a-service platform built specifically around this insight. Unlike broader metabolic health platforms that position glucose monitoring as one tool among many, Signos narrows its focus to a specific outcome: weight management through glucose optimization. The platform uses continuous glucose data, AI-driven algorithms, and personalized glucose targets to guide users toward eating patterns that minimize insulin spikes and create metabolic conditions favorable to fat utilization and sustained energy.

The approach is grounded in real physiology. A 2024 study published in Nature Medicine by Shilo and colleagues demonstrated that glucose variability in nondiabetic adults is far greater than standard testing reveals, with 40% of initially “normal” individuals reclassified as prediabetic under continuous monitoring. For people struggling with weight, this hidden glucose instability may be a significant, unrecognized contributor to metabolic resistance that no scale or calorie counter can detect.

What Is Signos?

Signos is a subscription-based platform that combines continuous glucose monitoring sensors with an AI-powered mobile app designed to optimize eating behavior for weight management. Users wear an FDA-cleared CGM sensor (typically a Dexcom or Abbott Libre model) and receive real-time glucose data through the Signos app, which adds personalized glucose targets, meal timing recommendations, and activity prompts based on the individual’s glucose patterns.

The platform’s central feature is a personalized glucose target zone. Rather than using a one-size-fits-all threshold, Signos’ AI establishes an individualized target based on the user’s glucose history, then provides real-time alerts and guidance when glucose moves above or below that target. The logic is straightforward: keeping glucose within a stable, individualized range minimizes insulin spikes, reduces the hormonal signaling that promotes fat storage, and creates metabolic conditions that favor fat oxidation.

The app provides meal recommendations based on glucose response data, exercise prompts when glucose is elevated (a post-meal walk, for example, can flatten a glucose spike by 20 to 40 mg/dL), and daily summaries that track progress toward glucose and weight goals. Over time, the AI refines its recommendations as it learns the user’s individual metabolic patterns.

Signos positions itself explicitly as a weight management tool, distinguishing it from broader metabolic health platforms like Levels Health and coaching-oriented platforms like Nutrisense. The focus is narrower but deeper: every feature is designed to support the specific goal of weight loss and metabolic optimization.

The Science Behind Glucose-Driven Weight Management

The relationship between glucose metabolism, insulin signaling, and body weight has been a central topic in metabolic research for decades. The core mechanism is well established: when blood glucose rises after a meal, the pancreas secretes insulin to facilitate glucose uptake by cells. Insulin also promotes fat storage and inhibits fat oxidation. Meals that produce large, rapid glucose spikes trigger correspondingly large insulin surges, creating a hormonal environment that favors energy storage over energy utilization.

Glycemic variability amplifies this effect. The broader medical research community has demonstrated that individuals with high glucose variability (large swings between peaks and troughs) experience more frequent insulin surges, greater inflammatory signaling, and more oxidative stress than individuals with stable glucose, even when their average glucose levels are similar. For people trying to manage weight, high glycemic variability creates a metabolic headwind that makes fat loss more difficult regardless of caloric intake.

The Shilo et al. 2024 study in Nature Medicine showed that glucose variability in nondiabetic adults is far greater than a single fasting test reveals, with day-to-day fasting glucose varying by 7.52 mg/dL within the same individual. This finding suggests that many people who believe their glucose is “normal” may be experiencing subclinical glycemic instability that contributes to weight management difficulties, energy crashes, and cravings.

CGM makes this variability visible, but Signos’ contribution is in translating visibility into action. The platform’s AI uses individual glucose response data to identify which foods, meal combinations, and eating times produce the most stable glucose for each user. Research on personalized nutrition, including the landmark Zeevi et al. study in Cell, has shown that glucose responses to identical foods vary dramatically between individuals. Signos operationalizes this finding by creating a personalized glucose optimization framework rather than relying on generic dietary guidelines.

A 2024 study in Nature Communications by Brandhorst et al. demonstrated that metabolic interventions can reduce biological age by 2.5 years. While that study focused on fasting-mimicking protocols rather than CGM-guided eating, the underlying principle is the same: sustained metabolic optimization produces measurable biological benefits, and the most effective interventions are those that target an individual’s specific metabolic profile.

What Signos Does Well

The personalized glucose target is Signos’ strongest feature. Rather than applying a universal threshold (the commonly cited 140 mg/dL postmeal target), Signos calculates an individualized target based on the user’s glucose history and metabolic responses. This means the platform adapts to each user’s biology, providing tighter targets for individuals who respond well to glucose optimization and more realistic targets for those starting from a less stable baseline.

The real-time activity prompts are clinically informed and practically useful. When glucose rises above the target after a meal, the app may suggest a brief walk, light movement, or specific activity. Post-meal walking has been shown in multiple studies to reduce glucose spikes by 20 to 40 mg/dL, and Signos makes this intervention timely and actionable by triggering it based on real-time glucose data rather than generic advice.

The weight management focus provides clarity of purpose. While broader platforms like Levels Health try to serve biohackers, athletes, and general metabolic health enthusiasts simultaneously, Signos keeps its features and messaging oriented around a single goal: sustainable weight loss through glucose optimization. For users whose primary motivation is weight management, this focused approach may feel more relevant and actionable than a general-purpose metabolic dashboard.

The AI learning component improves over time. As the platform accumulates more data about a user’s glucose patterns, food responses, and activity impact, its recommendations become increasingly personalized. The longer a user wears Signos, the more refined the guidance becomes.

Pricing, Access, and Practical Realities

Signos operates on a subscription model with pricing ranging from approximately $199 to $399 per month depending on commitment length and plan tier. The subscription includes CGM sensors and app access. Longer-term commitments typically reduce the per-month cost.

First-year cost of ownership ranges from approximately $2,388 to $4,788, placing Signos in the mid-to-premium tier of CGM platforms. The pricing is comparable to Nutrisense and higher than Levels Health or the Dexcom Stelo.

Signos handles the CGM prescribing process through telehealth partnerships, so a diabetes diagnosis is not required. The CGM sensors are HSA and FSA eligible. The platform requires a compatible smartphone for the app and sensor data.

The weight management positioning means that users should enter with clear weight-related goals. The platform is optimized for people who want to lose weight or improve body composition through glucose optimization, not for general metabolic exploration or athletic performance optimization. Users whose primary interest is metabolic health without a weight focus may find broader platforms more aligned with their needs.

Who Signos Is Best For

Signos is best suited for individuals whose primary health goal is weight management and who want a technology-driven approach to achieving it. The platform works particularly well for people who have struggled with traditional calorie-counting approaches and want to understand the metabolic dimension of their weight management challenges. Individuals with suspected insulin resistance, blood sugar swings that correlate with energy crashes and cravings, or a family history of type 2 diabetes will find the glucose-focused approach especially relevant.

People who respond well to AI-driven recommendations and real-time feedback loops will appreciate Signos’ activity prompts and meal guidance. The platform is designed for users who want specific, actionable instructions (“go for a walk now”) rather than abstract data to interpret on their own.

Consumers who may want to look elsewhere include those whose primary interest is general metabolic health without a weight management focus (Levels Health is broader). People who want human coaching should consider Nutrisense, which includes registered dietitian access. Budget-conscious users should note the premium pricing and consider whether the Dexcom Stelo at $99 per month could provide sufficient data for their goals.

How Signos Compares

Levels Health offers a broader metabolic health platform with the Metabolic Score, food response analysis, and Zone 2 exercise insights for approximately $199 per month. Levels serves a wider audience including athletes, biohackers, and general health optimizers. Signos is more focused on weight management with AI-driven glucose targets and activity prompts. Users whose goal is weight loss should evaluate both platforms based on which feature set better matches their preferred approach: data-driven self-direction (Levels) versus AI-guided weight management (Signos).

Nutrisense includes registered dietitian coaching at $225 to $399 per month. For users who want professional human guidance with their CGM data, Nutrisense provides a coaching relationship that Signos’ AI cannot fully replicate. Signos is the better choice for users who prefer algorithmic guidance over human coaching.

The Dexcom Stelo provides raw CGM data at $99 per month without analytics, coaching, or AI recommendations. It serves as the budget entry point to CGM. Users who try the Stelo and find they want more structured weight management guidance can upgrade to Signos for the AI layer.

Limitations and Open Questions

The weight management focus, while a strength for its target audience, limits the platform’s utility for users with broader health goals. Athletes seeking Zone 2 training insights, individuals monitoring autoimmune-related glucose patterns, or people primarily interested in longevity optimization may find Signos’ features too narrowly focused.

AI recommendation quality depends on the underlying data and algorithm. Users who do not consistently log meals, wear sensors continuously, or follow prompts may find the AI’s recommendations less personalized and useful. The system works best with engaged, consistent users who provide the data it needs to learn.

Clinical evidence specifically validating Signos’ AI-driven approach for weight loss outcomes has not been published in peer-reviewed journals. While the underlying science of glucose optimization for metabolic health is well supported, the proprietary algorithm’s effectiveness compared to standard dietary counseling or other CGM platforms remains unproven.

Cost is a barrier for sustained use. At $199 to $399 per month, Signos represents a significant ongoing investment. Users must evaluate whether the AI-driven insights produce enough behavioral change to justify the cost relative to lower-cost CGM options combined with free or lower-cost nutrition guidance.

What This Means for Your Health

Signos represents a focused application of continuous glucose monitoring to one of the most common health challenges people face: sustainable weight management. Within Healthcare Discovery‘s longevity framework, the platform connects the nutrition pillar to metabolic outcomes through a feedback loop that is both data-rich and action-oriented. The AI-driven glucose targets and activity prompts translate metabolic data into specific behavioral guidance, reducing the gap between knowing what your glucose does and knowing what to do about it.

The connections to the broader pillar framework are present even within the weight management focus. Sleep disruption elevates glucose and promotes insulin resistance, making weight management harder. Movement, particularly the brief post-meal walks that Signos recommends, produces measurable glucose-lowering effects. Stress management reduces cortisol-driven glucose elevations that trigger insulin surges and fat storage signaling. Even mindset benefits from the sense of control and understanding that comes from seeing your metabolic data in real time.

Metabolic dysfunction, one of the Four Villains that the broader medical research community identifies as a primary threat to longevity, is intimately connected to weight management. Excess body fat promotes insulin resistance, which promotes further fat storage, creating a cycle that accelerates metabolic aging. By optimizing glucose dynamics to break this cycle, platforms like Signos address one of the most modifiable risk factors for chronic disease. The platform does not diagnose or treat disease, but it provides a technology-driven pathway to the kind of metabolic optimization that longevity science increasingly recognizes as foundational to healthspan.

Frequently Asked Questions

How does Signos use CGM data for weight loss?

Signos analyzes your continuous glucose data to establish personalized glucose targets, then provides real-time recommendations to keep your glucose within that target zone. When glucose spikes above target after a meal, the app may prompt a walk or activity. Over time, the AI learns your individual food responses and suggests meals and timing patterns that minimize insulin spikes and create metabolic conditions favorable to fat loss.

How much does Signos cost?

Signos subscriptions range from approximately $199 to $399 per month, with lower per-month pricing for longer commitments. The subscription includes CGM sensors and full app access. First-year cost ranges from $2,388 to $4,788 depending on the plan. CGM sensors are HSA and FSA eligible.

Do I need a prescription for Signos?

Signos handles the CGM prescribing process through integrated telehealth partnerships. You do not need an existing prescription or diabetes diagnosis. The platform connects you with a licensed prescriber who can authorize the CGM sensors as part of your Signos subscription.

How does Signos compare to Levels Health?

Signos focuses specifically on weight management through AI-driven glucose targets and activity prompts ($199 to $399/month). Levels Health is a broader metabolic health platform with the Metabolic Score, food response analysis, and Zone 2 exercise insights ($199/month). Users whose primary goal is weight loss should evaluate which approach better matches their style: AI-guided weight management (Signos) versus self-directed metabolic optimization (Levels).

Does Signos include coaching or dietitian access?

Signos relies on its AI algorithm rather than human coaching. The platform provides automated recommendations, activity prompts, and meal guidance based on your glucose data. It does not include registered dietitian access. For users who want human professional coaching alongside CGM data, Nutrisense is the primary alternative, bundling RD coaching with sensors at $225 to $399 per month.

How quickly can I expect to see results with Signos?

Signos reports that most users begin seeing glucose pattern improvements within the first week of use and that the AI’s recommendations become more personalized over the first month as it learns your individual metabolic responses. Weight loss timelines vary based on starting point, adherence, and other lifestyle factors. The platform is designed for sustained use rather than rapid results, with multi-month programs reflecting this long-term approach.

{“@context”:”https://schema.org”,”@type”:”FAQPage”,”mainEntity”:[{“@type”:”Question”,”name”:”How does Signos use CGM data for weight loss?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Signos analyzes your continuous glucose data to establish personalized glucose targets, then provides real-time recommendations to keep glucose within that zone. When glucose spikes after a meal, the app may prompt a walk or activity. Over time, the AI learns your individual food responses and suggests meals and timing patterns that minimize insulin spikes and create metabolic conditions favorable to fat loss.”}},{“@type”:”Question”,”name”:”How much does Signos cost per year?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Signos subscriptions range from approximately $199 to $399 per month, with lower pricing for longer commitments. The subscription includes CGM sensors and full app access. First-year cost ranges from $2,388 to $4,788 depending on the plan selected. CGM sensors are HSA and FSA eligible.”}},{“@type”:”Question”,”name”:”Do I need a prescription to use Signos?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Signos handles the CGM prescribing process through integrated telehealth partnerships. You do not need an existing prescription or diabetes diagnosis. The platform connects you with a licensed prescriber who can authorize the CGM sensors as part of your subscription.”}}]}